CATUG will attend BioProcess International 2026, taking place September 22–25 at the Hynes Convention Center in Boston.

For RNA and advanced therapy programs, current development challenges increasingly center on the transition from early formulation to clinical manufacturing: aligning RNA design with LNP performance, defining critical quality attributes, establishing comparability across scales and equipment, and preparing complex (t)LNP products for repeatable GMP production.

CATUG’s integrated platform connects plasmid DNA, xRNA, LNP/tLNP development, analytical development and QC, and GMP manufacturing, aseptic fill-finish and lyophilization. Supported by flexible manufacturing capacity and an internationally aligned quality system, the platform accommodates rapid IIT supply and early clinical validation while maintaining CMC continuity for IND development, process scale-up and clinical-stage manufacturing.

Visit Booth SU11 from September 23–25 to discuss LNP formulation screening, targeted delivery, process scale-up, analytical strategy, IIT supply and GMP readiness with our team.

BioProcess International 2026

September 22–25 | Hynes Convention Center, Boston

Exhibition: September 23–25 | Booth SU11

Business Enquiries: BD@catugbio.com

LinkedIn: CATUG Biotechnology